The Quantellect read.As of Nov 19, 2026, 17 active firms cover ACADIA Pharmaceuticals Inc: 13 rate it Buy or better, 4 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $23.00 to $37.00, a moderate spread. The average target of $31.82 sits 78% above the current $17.83. The rating mix has stayed broadly stable, with Buy-side ratings easing from 14 to 13 over recent months. On the fundamentals, the Street sees revenue growth near 16% this year and 12% next, consensus EPS building from about $0.23 next quarter toward $1.08 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS17 active firms
Buy
Strong Buy00%
Buy1376%
Neutral424%
Sell00%
Strong Sell00%
Based on 17 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$31.82
+78.5% upside
Average target across 17 active firms as of Nov 19, 2026 vs $17.83 current
Highest Target$37.00
Average Target$31.82
Lowest Target$23.00
Detailed analyst forecasts for ACAD
Showing 1–18 of 18 named analysts shown · 17 active firms in the rating projection
As of Nov 19, 2026, 13 of 17 active firms rate ACAD a Buy (4 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ACAD EPS & revenue forecast
EPS · NEXT QUARTER
$0.23
Range $0.12 – $0.35 · 4 analysts · +1075% YoY
Next period, 4 analysts expect ACADIA Pharmaceuticals Inc to earn $0.23 a share (range $0.12 – $0.35), versus $0.02 a year earlier. Full-year consensus is $0.76, growing to $1.08 the year after.
REVENUE · NEXT QUARTER
$350.8M
Range $340.0M – $358.0M · 4 analysts · +17% YoY
Revenue is expected to reach $350.8M (range $340.0M – $358.0M), +17.0% year-over-year. Full-year consensus is $1.3B, rising to $1.5B next year.
Top analysts covering ACADIA Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ACAD.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #10
Neutral
$28.00+57.0% to target
Overall win rate
64%
+ Follow
#2
Jason Butler
JMP Securities · Rank #62
Buy
$33.00+85.1% to target
Overall win rate
49%
+ Follow
#3
Joel Beatty
Baird · Rank #71
Buy
$31.00+73.9% to target
Overall win rate
50%
+ Follow
#4
Ami Fadia
Needham · Rank #92
Buy
$35.00+96.3% to target
Overall win rate
46%
+ Follow
#5
Sarah James
Cantor Fitzgerald · Rank #159
Buy
$28.00+57.0% to target
Overall win rate
37%
+ Follow
ACAD stock forecast FAQ
What is ACAD's average 12-month price target?+
The 17 active firms with a live target average $31.82 for ACADIA Pharmaceuticals Inc over the next 12 months, ranging from a $37.00 high to a $23.00 low, as of Nov 19, 2026.
Is ACAD stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 17 active firms as of Nov 19, 2026, 13 rate it Buy or Strong Buy, 4 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ACAD?+
The Street-high target is $37.00 (TD Cowen), and the Street-low is $23.00 (UBS). The average of all 17 active-firm targets is $31.82.
How many active Wall Street firms cover ACAD?+
17 active firms have a recognized rating on ACADIA Pharmaceuticals Inc as of Nov 19, 2026, and 17 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ACAD?+
Among analysts who currently cover ACAD, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #10). Their current call is Neutral with a $28.00 target.
What is ACADIA Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.23 per share (range $0.12 – $0.35) across 4 analysts. Full-year EPS is projected at $0.76, rising to $1.08 the following year.
How much revenue is ACADIA Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $350.8M (range $340.0M – $358.0M). Full-year revenue is projected at $1.3B, growing to $1.5B next year.
Have analysts been upgrading or downgrading ACAD lately?+
As of Nov 19, 2026, 13 of 17 active firms rate ACAD a Buy (4 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ACAD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.